How would you manage axial spondyloarthritis in a patient who was doing well on TNF inhibitor therapy then developed a new solid organ malignancy while on treatment?
How does the management differ if the cancer is resectable or requires systemic treatment?
Answer from: at Academic Institution
The story here is an important one. I was able to discuss this with @Jonathan Kay, who supplied important insights. Most of the good (and bad) data supporting what to do when your patient had a prior malignancy in remission or who develops one on treatment comes from experience with treating rheumat...